Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司,主要致力于 Hydronidone (F351) 的开发和商业化,该药物被用于治疗代谢功能障碍相关的脂肪性肝炎(MASH 相关肝纤维化(MASH 纤维化),以前在美国被称为非酒精性脂肪性肝炎(NASH)。 在美国,Hydronidone 目前在积极的试验性新药 (IND) 的申请中...
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalco...
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalco...
Current Price $25.00 NASDAQ: AMPH Amphastar Pharmaceuticals Market Cap $2B Current Price $48.02 Premium Investing Services Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. ...
用富途牛牛查看Gyre Therapeutics (GYRE)的股票价格、新闻、历史走势图、分析师评级、财务信息和行情。使用富途牛牛免佣金股票交易App进行交易。
Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, with a primary focus on the development and commercialization of Hydronidone (F351) for the treatment of NASH-associated fibrosis in the United States. Gyre’s development strategy for F351 in NASH ...
These findings further enhance our understanding of hydronidone and underscore its therapeutic potential in treating liver fibrosis." Show More Stock_TitanJun 19, 2024 4:05 AM $GYRE Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology stocktitan.net/news/GYRE/gy... ...
F351 (Hydronidone): Manuscript highlighting preclinical data published in the Journal of Gastroenterology and Hepatology.In June 2024, Gyre Therapeutics announced the publication of the manuscript titled “Hydronidone induces apoptosis in activated hepatic stellate cells through endoplasmic reticulum stress-as...
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalco...
用富途牛牛查看Gyre Therapeutics (GYRE)的股票价格、新闻、历史走势图、分析师评级、财务信息和行情。使用富途牛牛免佣金股票交易App进行交易。